Fulcrum Therapeutics Inc (FULC)

May 03, 2025

Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN

May 03, 2025

May 02, 2025

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News

May 02, 2025

May 02, 2025

Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com

May 02, 2025

May 02, 2025

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance

May 02, 2025

May 01, 2025

Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks

May 01, 2025

May 01, 2025

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa

May 01, 2025

May 01, 2025

Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com

May 01, 2025

May 01, 2025

Fulcrum Therapeutics Inc Q1 2025 Earnings: EPS of -$0.28 Beats E - GuruFocus

May 01, 2025

May 01, 2025

FULC Achieves Milestone in Sickle Cell Disease Treatment Development | FULC Stock News - GuruFocus

May 01, 2025

May 01, 2025

FULC Financial Update: Cash Position Shifts in Early 2025 | FULC Stock News - GuruFocus

May 01, 2025

May 01, 2025

Fulcrum Therapeutics (FULC) Target Price Adjusted Amid Strong Ca - GuruFocus

May 01, 2025

May 01, 2025

Are Fulcrum Therapeutics Inc’shares a good deal? - uspostnews.com

May 01, 2025

May 01, 2025

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss - Investing.com

May 01, 2025

May 01, 2025

Fulcrum Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025

May 01, 2025

Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 2c - StreetInsider

May 01, 2025

May 01, 2025

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 - The Manila Times

May 01, 2025

May 01, 2025

Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView

May 01, 2025

Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025

Apr 26, 2025

Geode Capital Management LLC Sells 26,347 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Apr 26, 2025

Apr 25, 2025

Daily Progress: Fulcrum Therapeutics Inc (FULC) Drop -10.27, Closing at 3.32 - DWinneX

Apr 25, 2025

Apr 24, 2025

Fulcrum Therapeutics Inc [NASDAQ: FULC] Sees Decrease in Stock Value - knoxdaily.com

Apr 24, 2025

Apr 24, 2025

Fulcrum Therapeutics to Release First Quarter 2025 Financial Results on May 1, 2025 - Nasdaq

Apr 24, 2025

Apr 24, 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET - The Manila Times

Apr 24, 2025

Apr 24, 2025

Earnings Call Alert: Rare Disease Developer Fulcrum Therapeutics Sets Q1 2025 Results Date - Stock Titan

Apr 24, 2025

Apr 23, 2025

Investing in Fulcrum Therapeutics Inc (FULC) might be a great opportunity, but the stock is a bit overvalued - uspostnews.com

Apr 23, 2025

Apr 22, 2025

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $8.63 - Defense World

Apr 22, 2025

Apr 14, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Wellington Management Group LLP - Defense World

Apr 14, 2025

Apr 13, 2025

American Century Companies Inc. Increases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Apr 13, 2025

Apr 12, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus

Apr 12, 2025

Apr 11, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 11, 2025

Apr 08, 2025

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance

Apr 08, 2025

Apr 08, 2025

Fulcrum Therapeutics, Inc. (FULC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Apr 08, 2025

Apr 07, 2025

Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Apr 07, 2025

Apr 04, 2025

Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry - simplywall.st

Apr 04, 2025

Apr 01, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India

Apr 01, 2025

Apr 01, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.77 By Investing.com - Investing.com UK

Apr 01, 2025

Mar 29, 2025

Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Mar 29, 2025

Mar 28, 2025

Fulcrum Sheds Investor Suit Over Blood Treatment Trial Safety - Bloomberg Law News

Mar 28, 2025

Mar 28, 2025

Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World

Mar 28, 2025

Mar 16, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire

Mar 16, 2025

Mar 11, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India

Mar 11, 2025

Mar 11, 2025

Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK

Mar 11, 2025

Mar 06, 2025

Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationFULC - ACCESS Newswire

Mar 06, 2025

Mar 05, 2025

Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Benzinga

Mar 05, 2025